Runze Shang

3.9k total citations · 1 hit paper
32 papers, 2.8k citations indexed

About

Runze Shang is a scholar working on Molecular Biology, Cancer Research and Pathology and Forensic Medicine. According to data from OpenAlex, Runze Shang has authored 32 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Molecular Biology, 17 papers in Cancer Research and 7 papers in Pathology and Forensic Medicine. Recurrent topics in Runze Shang's work include Cancer-related molecular mechanisms research (7 papers), Cancer Mechanisms and Therapy (6 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Runze Shang is often cited by papers focused on Cancer-related molecular mechanisms research (7 papers), Cancer Mechanisms and Therapy (6 papers) and Cancer, Hypoxia, and Metabolism (6 papers). Runze Shang collaborates with scholars based in China, United States and Germany. Runze Shang's co-authors include Shibin Qu, Haimin Li, Xisheng Yang, Jianlin Wang, Kefeng Dou, Xiaolei Li, Wei Sun, Yuan Gao, Desheng Wang and Wenjie Song and has published in prestigious journals such as Hepatology, Cancer Research and Gut.

In The Last Decade

Runze Shang

31 papers receiving 2.7k citations

Hit Papers

Circular RNA: A new star of noncoding RNAs 2015 2026 2018 2022 2015 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Circular RNA: A new star of noncoding RNAs
    2015 1.4k citations Shibin Qu, Xisheng Yang et al. Cancer Letters profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Runze Shang China 21 2.4k 2.0k 173 161 146 32 2.8k
Jinzhao Ma China 16 2.7k 1.1× 2.4k 1.2× 201 1.2× 110 0.7× 182 1.2× 36 3.2k
Yaming Li China 26 2.1k 0.9× 1.8k 0.9× 250 1.4× 191 1.2× 318 2.2× 77 2.6k
Amy Lam Hong Kong 6 1.2k 0.5× 845 0.4× 268 1.5× 185 1.1× 120 0.8× 7 1.8k
Pengcheng Jiang China 24 1.4k 0.6× 1.1k 0.6× 151 0.9× 125 0.8× 203 1.4× 59 1.8k
Tae Matsumura Japan 15 1.1k 0.5× 900 0.4× 290 1.7× 120 0.7× 174 1.2× 66 1.6k
Pu Li China 24 1.3k 0.5× 997 0.5× 330 1.9× 153 1.0× 89 0.6× 52 1.7k
Xiaoyan Wang China 22 1.2k 0.5× 1.2k 0.6× 178 1.0× 203 1.3× 156 1.1× 70 1.7k

Countries citing papers authored by Runze Shang

Since Specialization
Citations

This map shows the geographic impact of Runze Shang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Runze Shang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Runze Shang more than expected).

Fields of papers citing papers by Runze Shang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Runze Shang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Runze Shang. The network helps show where Runze Shang may publish in the future.

Co-authorship network of co-authors of Runze Shang

This figure shows the co-authorship network connecting the top 25 collaborators of Runze Shang. A scholar is included among the top collaborators of Runze Shang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Runze Shang. Runze Shang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Pan, Zhiqiang, Runze Shang, Xinya Zhang, et al.. (2022). Case Report: Tachycardia, Hypoxemia and Shock in a Severely Burned Pediatric Patient. Frontiers in Cardiovascular Medicine. 9. 904400–904400. 3 indexed citations
3.
Liu, Ze-Kun, Renyu Zhang, Ling‐Min Kong, et al.. (2022). Pyroptosis-Related LncRNA Signature Predicts Prognosis and Is Associated With Immune Infiltration in Hepatocellular Carcinoma. Frontiers in Oncology. 12. 794034–794034. 13 indexed citations
4.
Xu, Hongwei, Kefei Chen, Runze Shang, et al.. (2021). Alpelisib combination treatment as novel targeted therapy against hepatocellular carcinoma. Cell Death and Disease. 12(10). 920–920. 20 indexed citations
5.
Xu, Meng, Haichuan Wang, Jingxiao Wang, et al.. (2020). mTORC2 Signaling Is Necessary for Timely Liver Regeneration after Partial Hepatectomy. American Journal Of Pathology. 190(4). 817–829. 14 indexed citations
6.
Wang, Pan, Xinhua Song, Dan Cao, et al.. (2020). Oncogene-dependent function of BRG1 in hepatocarcinogenesis. Cell Death and Disease. 11(2). 91–91. 27 indexed citations
7.
Shang, Runze, Xinhua Song, Pan Wang, et al.. (2020). Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma. Gut. 70(9). 1746–1757. 75 indexed citations
8.
Wang, Pan, Xinhua Song, Kirsten Utpatel, et al.. (2019). MEK inhibition suppresses K-Ras wild-type cholangiocarcinoma in vitro and in vivo via inhibiting cell proliferation and modulating tumor microenvironment. Cell Death and Disease. 10(2). 120–120. 7 indexed citations
9.
Wang, Miao, Shuai Zhang, Qian Sun, et al.. (2019). Dual effects of an anti-CD147 antibody for Esophageal cancer therapy. Cancer Biology & Therapy. 20(12). 1443–1452. 11 indexed citations
10.
11.
Dai, Bin, Xuan Zhang, Runze Shang, et al.. (2018). Blockade of ARHGAP11A reverses malignant progress via inactivating Rac1B in hepatocellular carcinoma. Cell Communication and Signaling. 16(1). 99–99. 35 indexed citations
12.
Wang, Jianlin, Congcong Xia, Meng Pu, et al.. (2018). Silencing of CDCA5 inhibits cancer progression and serves as a prognostic biomarker for hepatocellular carcinoma. Oncology Reports. 40(4). 1875–1884. 21 indexed citations
13.
Pu, Meng, Jianlin Wang, Qike Huang, et al.. (2017). High MRPS23 expression contributes to hepatocellular carcinoma proliferation and indicates poor survival outcomes. Tumor Biology. 39(7). 3726132512–3726132512. 34 indexed citations
14.
Wang, Jianlin, Wenjie Song, Weiwei Shen, et al.. (2017). MicroRNA-200a Suppresses Cell Invasion and Migration by Directly Targeting GAB1 in Hepatocellular Carcinoma. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 25(1). 1–10. 25 indexed citations
15.
Lv, Xing, Cheng Fang, Runze Shang, et al.. (2017). Agrin para-secreted by PDGF-activated human hepatic stellate cells promotes hepatocarcinogenesis in vitro and in vivo. Oncotarget. 8(62). 105340–105355. 29 indexed citations
16.
Shang, Runze, Shibin Qu, & Desheng Wang. (2016). Reprogramming of glucose metabolism in hepatocellular carcinoma: Progress and prospects. World Journal of Gastroenterology. 22(45). 9933–9933. 103 indexed citations
17.
Shang, Runze, Jianlin Wang, Wei Sun, et al.. (2015). RRAD inhibits aerobic glycolysis, invasion, and migration and is associated with poor prognosis in hepatocellular carcinoma. Tumor Biology. 37(4). 5097–5105. 22 indexed citations
18.
Qu, Shibin, Xisheng Yang, Xiaolei Li, et al.. (2015). Circular RNA: A new star of noncoding RNAs. Cancer Letters. 365(2). 141–148. 1419 indexed citations breakdown →
19.
Qu, Shibin, Xisheng Yang, Wenjie Song, et al.. (2015). Downregulation of lncRNA-ATB correlates with clinical progression and unfavorable prognosis in pancreatic cancer. Tumor Biology. 37(3). 3933–3938. 51 indexed citations
20.
Dai, Bin, Bai Ruan, Juan Wu, et al.. (2014). Insulin-like growth factor binding protein-1 inhibits cancer cell invasion and is associated with poor prognosis in hepatocellular carcinoma.. PubMed. 7(9). 5645–54. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jinzhao Ma Breakdown of academic impact, for papers by Yaming Li Breakdown of academic impact, for papers by Amy Lam Breakdown of academic impact, for papers by Pengcheng Jiang Breakdown of academic impact, for papers by Tae Matsumura Breakdown of academic impact, for papers by Pu Li Breakdown of academic impact, for papers by Xiaoyan Wang
Rankless by CCL
2026